Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shide k. Ann Lab Med. 2017 Mar;37(2):159-161. doi: 10.3343/alm.2017.37.2.159. Ann Lab Med. 2017. PMID: 28029004 Free PMC article. No abstract available.
The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K, Kubuki Y, Nagata K, Takenaka K, Akashi K, Okamura T, Niho Y, Mizoguchi H, Omine M, Ozawa K, Harada M, Shimoda K. Hidaka T, et al. Among authors: shide k. Eur J Haematol. 2009 Oct;83(4):328-33. doi: 10.1111/j.1600-0609.2009.01298.x. Epub 2009 Jun 15. Eur J Haematol. 2009. PMID: 19549278
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K. Shide K, et al. Blood. 2011 Jun 23;117(25):6866-75. doi: 10.1182/blood-2010-01-262535. Epub 2011 Apr 29. Blood. 2011. PMID: 21531978 Free article.
Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
Kawano N, Ochiai H, Yoshida S, Yamashita K, Shide K, Shimoda H, Hidaka T, Kubuki Y, Katayose K, Toyama T, Kawano H, Matsuoka H, Ishizaki J, Maeda K, Satou S, Yano T, Yamaguchi K, Takenaka K, Shimao Y, Oshima K, Ueda A, Shimoda K. Kawano N, et al. Among authors: shide k. Int J Clin Oncol. 2012 Aug;17(4):336-40. doi: 10.1007/s10147-011-0292-5. Epub 2011 Sep 10. Int J Clin Oncol. 2012. PMID: 21904968
Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation.
Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M, Yamamoto S, Hidaka T, Kubuki Y, Yokokura S, Uemura M, Matsuoka A, Waki F, Matsumoto K, Kanaji N, Ishii T, Imataki O, Dobashi H, Bandoh S, Shimoda K. Matsunaga T, et al. Among authors: shide k. Ann Hematol. 2012 Oct;91(10):1633-43. doi: 10.1007/s00277-012-1498-y. Epub 2012 May 29. Ann Hematol. 2012. PMID: 22644786
104 results